Prognosis of prostate cancer is determined by three clinical factors: PSA, Gleason score, and tumor stage. The likelihood of prostate cancer death in each patient after radical therapy can be predicted using nomograms. KLK2 is a good prognostic indicator for prostate cancer, and KLK2 analysis alone or in conjunction with P-binding protein 3SA analysis may be helpful. New prognostic biomarkers are needed to improve clinical care and differentiate between indolent and aggressive illness. IGFBP-3 is an insulin-like growth factor that is involved in the suppression of cell proliferation and the increased cytotoxicity of prostate cancer cells to VD3 when combined with the anti-cancer medication. It is also used in the risk of bone metastases. EPCA-2 is a putative serum tumor marker in prostate cancer and can be used to distinguish between local and metastatic prostate cancer. PSCA expression is associated with tumor stage, grade, and androgen independence. PSCA is a helpful molecular target in advanced prostate cancer due to its ability to increase extracellular matrix and basement membrane breakdown, which is necessary for metastasis and spread locally. Urokinase plasminogen activator receptor (uPAR) on the cell surface is where (uPAR) binds and is broken down into plasmin. uPAR participates in a number of immune regulatory systems and also indicates the degree of immune system activation. uPAR levels during infectious infections and among patients receiving treatment in critical care units have been the subject of several studies, and may have predictive significance in determining the likelihood of developing diabetes, hypertension, and cardiovascular disease.